Valeant Pharmaceuticals Intl Inc (TSE:VRX) had its price target decreased by stock analysts at Scotiabank from C$32.00 to C$17.00 in a research report issued to clients and investors on Wednesday. The firm presently has a “sector perform” rating on the specialty pharmaceutical company’s stock. Scotiabank’s price target suggests a potential downside of 25.11% from the company’s current price.

A number of other research firms also recently commented on VRX. Royal Bank Of Canada reaffirmed an “outperform” rating and set a C$46.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Monday, October 3rd. TD Securities reaffirmed a “buy” rating and set a C$38.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, August 10th.

Valeant Pharmaceuticals Intl (TSE:VRX) opened at 22.70 on Wednesday. The firm has a 50-day moving average price of $29.46 and a 200 day moving average price of $33.06. Valeant Pharmaceuticals Intl has a 1-year low of $18.41 and a 1-year high of $165.77. The company’s market capitalization is $7.89 billion.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.